IBD Pharm

Question 1

Sulfasalazine

Answer 1

• treatment for ULCERATIVE COLITIS

- 5-ASA (inhibits production of PG and LT from arachadonic path)

Question 2

Mesalamine

Answer 2

• treatment for ULCERATIVE COLITIS

- 5-ASA (inhibits production of PG and LT from arachadonic path)

Question 3

Olsalazine

Answer 3

• treatment for MAINTENANCE OF REMISSION FOR ULCERATIVE COLITIS
• 5-ASA (inhibits production of PG and LT from arachadonic path)

Question 4

Balsalazine

Answer 4

• treatment for ACTIVE DZ ULCERATIVE COLITIS

- 5-ASA (inhibits production of PG and LT from arachadonic path)

Question 5

Tofacitinib

Answer 5

• treatment for ULCERATIVE COLITIS

- Janus Kinase (JAK) Inhibitor (prevents phosphorylation)

Question 6

Ustekinumab

Answer 6

• treatment for BOTH ULCERATIVE COLITIS AND CHROHN DISEASE
• IL-12/IL-23 Inhibitor (block p40 s/u of IL)
• risk of reactivating TB

Question 7

Adalimumab

Answer 7

• treatment for BOTH ULCERATIVE COLITIS AND CHROHN DISEASE
• TNF-α Inhibitor
• risk of reactivating TB

Question 8

Golimumab

Answer 8

• treatment for ULCERATIVE COLITIS
• TNF-α Inhibitor
• risk of reactivating TB

Question 9

Certolizumab

Answer 9

• treatment for CHROHN DISEASE
• TNF-α Inhibitor
• risk of reactivating TB

Question 10

Infliximab

Answer 10

• treatment for:
  - severe ULCERATIVE COLITIS
  - moderate CHROHN DISEASE
• TNF-α Inhibitor
• risk of reactivating TB

Question 11

Vedolizumab

Answer 11

• treatment for BOTH ULCERATIVE COLITIS AND CHROHN DISEASE
• α-4β7 Integrin Inhibitor (inhibit cell adhesion)
• risk of PML and infection
• require close monitoring with TOUCH program

Question 12

Natalizumab

Answer 12

• treatment for CHROHN DISEASE
• α-4β1 and α-4β7 Integrin Inhibitor (inhibit cell adhesion)
• risk of PML and infection
• require close monitoring with TOUCH program